buparlisib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Buparlisib is an experimental anti-cancer medication. It is a small molecule orally-available pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. Buparlisib was under investigation as a treatment for advanced breast cancer but was abandoned due to negative results. It is still under investigation as a potential treatment for head and neck squamous cell carcinoma (HNSCC).   Wikipedia

Chemistry

  • SMILES: Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F
  • InChIKey: CWHUFRVAEUJCEF-UHFFFAOYSA-N
  • Mol. Mass: 410.4
  • ALogP: 1.81
  • ChEMBL Molecule:
    buparlisib  
More Chemistry

Pharmacology

Alternative names

bkm120 | bkm 120 | bkm-120 | bkm120-nx | bmk120 | buparlisib | nvp-bkm120

Organizations (57)

Research & Development (57)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (47)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (47)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Verrucous (Phase 1/Phase 2)

Cholangiocarcinoma (Phase 2)

Colonic Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 2)

Drug Evaluation (Phase 1)

Drugs, Investigational (Phase 1)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Graft vs Host Disease (Phase 1/Phase 2)

Head and Neck Neoplasms (Phase 3)

Hypopharyngeal Neoplasms (Phase 1)

Kidney Failure, Chronic (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Melanoma (Phase 2)

Nasopharyngeal Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Primary Myelofibrosis (Phase 1)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Safety (Phase 1)

Salivary Gland Neoplasms (Phase 1/Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 1)

Thymoma (Phase 2)

Thyroid Neoplasms (Phase 2)

Tongue Neoplasms (Phase 1/Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 89
  • # of Trial Organizations: 57

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue